# Sac-TMT for Active TNBC Brain Metastases

Source: https://onco.cc/trials/nct07458113/  
OnCo record `nct07458113` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Yale University, not yet recruiting.

## Summary

Sac-TMT for Active TNBC Brain Metastases is a phase 2, interventional study registered as NCT07458113 by Yale University, with a registry enrolment figure of 20 participants, started 2026-08 and due to reach its primary completion in 2028-08. Interventions recorded: Sacituzumab tirumotecan. Conditions listed: Metastatic Triple Negative Breast Cancers. Triple-negative eligibility wording from the registry: "Histologically and/or cytologically confirmed metastatic triple-negative breast cancer defined by estrogen receptor (ER) expression \<10%, progesterone receptor expression \<10% and HER2-negative status, defined by 0, 1+ or 2+ FISH negative by immunohistochemistry (IHC) by standard pathology". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: BERLIN
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07458113
- Phase: 2
- Setting: Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer
- Sponsor: Yale University
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07458113: https://clinicaltrials.gov/study/NCT07458113

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)

---
JSON: https://onco.cc/api/v1/entities/nct07458113.json